Skip to main content

Arvinas, Inc.

corporate_fare Company Profile

Arvinas, Inc.

ARVN·NASDAQ·Life Sciences·CIK 0001655759

Arvinas, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for debilitating and life-threatening diseases. The company utilizes its PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform to develop a new class of therapeutics. These therapeutics are designed to use the body's natural protein disposal system to selectively degrade and remove disease-causing proteins. Arvinas has developed and optimized its proprietary PROTAC Discovery Engine to identify PROTAC therapeutics for diseases caused by abnormal proteins or aberrant protein expression. The company believes its targeted protein degradation approach is a novel therapeutic modality that may offer advantages over existing therapies and target a broad range of proteins, including those previously considered undruggable. Over the past five years, seven programs developed using Arvinas's PROTAC protein degradation platform have advanced to clinical trials in oncology and neurology indications, following preclinical studies demonstrating potent and selective protein degradation. The U.S. Food and Drug Administration, or FDA, has accepted the company's New Drug Application, or NDA, for vepdegestrant, its most advanced product candidate from the platform. Vepdegestrant is intended for the treatment of patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), or ER+/HER2-, estrogen receptor 1, or ESR1,-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy. The FDA has assigned a Prescription Drug User Fee Act, or PDUFA, action date of June 5, 2026, for vepdegestrant.

Arvinas, Inc. (NASDAQ:ARVN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ARVN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ARVN spans 10-Q, 8-K, DEF 14A, 10-K.

Recent high-impact activity:

  • Arvinas 10-Q: $558.9M Cash Funds Operations Into 2H 2028 After $53.9M Q3 Loss
  • Arvinas Posts $0.82 Q3 Loss as Revenue Collapses to $0.5M; Cash Runway to 2H 2028
  • Arvinas Posts 82-Cent Quarterly Loss as Profitability Fades
  • Arvinas' ARV-102 Shows Oculomotor and Biomarker Improvements in Parkinson's Phase 1
  • Arvinas Doses First Patient in Phase 1/2 Trial of First-in-Class HPK1 Degrader

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$262.6M
Net Income
-$80.8M
Diluted EPS
-$1.14
Op. Cash Flow
-$273.8M
Free Cash Flow
-$275.7M
Operating Income
-$118.5M
Cash & Equivalents
$142.9M
Total Debt
$600K
Debt / Equity
0.00×
Net Margin
-30.8%
Shares Outstanding
63.5M sh
Source: 10-K · filed 2026-02-24 · accession 0001628280-26-011226

Short Interest & Short Volume

7.59 days to cover

FINRA reported short interest of 5,751,346 shares in ARVN as of the October 30, 2026 settlement, a 2.8% increase from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 68.9% of ARVN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,751,346 shares as of October 30, 2026
Change vs prior period▲ 2.8%
Days to cover7.59 at avg daily volume of 757,464
Daily short volume (FINRA facilities)68.9% of 471,162 shares on November 20, 2026
5-day average short volume58.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ARVN, detected from its recent SEC filings.

ATM program1 shelf registration

New $400M Shelf Registered · $200M At-The-Market Program

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$6.46
52-week range · as of 2026-11-03 $6.46 – $14.51
Market cap
$423.03M
Volume
1.1M (1.2× avg)
3-mo avg 935.4K
Live data · 2026-11-21 06:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARVN - Latest Insights

ARVN
Nov 03, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.09
Real-time Price: $6.46 info
Change: -$0.630 (-9%) info
Market Cap: $423.033M info
ARVN
Nov 03, 2026, 8:09 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.06
Real-time Price: $6.46 info
Change: -$0.600 (-8%) info
Market Cap: $423.033M info
ARVN
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.46 info
Change: -$1.06 (-14%) info
Market Cap: $423.033M info
ARVN
Oct 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.46 info
Change: -$1.06 (-14%) info
Market Cap: $423.033M info
ARVN
Sep 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.60
Real-time Price: $6.46 info
Change: -$1.14 (-15%) info
Market Cap: $423.033M info
ARVN
Aug 04, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $9.00
Real-time Price: $6.46 info
Change: -$2.54 (-28%) info
Market Cap: $423.033M info
ARVN
Aug 04, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.43
Real-time Price: $6.46 info
Change: -$1.97 (-23%) info
Market Cap: $423.033M info
ARVN
Jun 22, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.74
Real-time Price: $6.46 info
Change: -$1.28 (-17%) info
Market Cap: $423.033M info
ARVN
Jun 16, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.42
Real-time Price: $6.46 info
Change: -$0.960 (-13%) info
Market Cap: $423.033M info
ARVN
Jun 02, 2026, 4:58 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.95
Real-time Price: $6.46 info
Change: -$1.49 (-19%) info
Market Cap: $423.033M info
ARVN
Jun 02, 2026, 5:43 AM EDT
Source: Zawya
Importance Score:
7
Price at Filing: $8.56
Real-time Price: $6.46 info
Change: -$2.10 (-25%) info
Market Cap: $423.033M info
ARVN
May 12, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.15
Real-time Price: $6.46 info
Change: -$3.69 (-36%) info
Market Cap: $423.033M info
ARVN
May 12, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.15
Real-time Price: $6.46 info
Change: -$3.69 (-36%) info
Market Cap: $423.033M info
ARVN
May 11, 2026, 5:21 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $9.68
Real-time Price: $6.46 info
Change: -$3.22 (-33%) info
Market Cap: $423.033M info
ARVN
May 11, 2026, 5:18 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.68
Real-time Price: $6.46 info
Change: -$3.22 (-33%) info
Market Cap: $423.033M info
ARVN
May 01, 2026, 12:58 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.27
Real-time Price: $6.46 info
Change: -$3.81 (-37%) info
Market Cap: $423.033M info
ARVN
May 01, 2026, 12:43 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $10.27
Real-time Price: $6.46 info
Change: -$3.81 (-37%) info
Market Cap: $423.033M info
ARVN
Apr 29, 2026, 9:23 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $10.19
Real-time Price: $6.46 info
Change: -$3.73 (-37%) info
Market Cap: $423.033M info
ARVN
Mar 18, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $12.22
Real-time Price: $6.46 info
Change: -$5.76 (-47%) info
Market Cap: $423.033M info
ARVN
Feb 24, 2026, 5:18 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $12.37
Real-time Price: $6.46 info
Change: -$5.91 (-48%) info
Market Cap: $423.033M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets